James Bligh's most recent trade in Conduit Pharmaceuticals Inc was a trade of 1,890,000 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on Nov. 18, 2024.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Conduit Pharmaceuticals Inc | James Bligh | Director, Interim CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Nov 2024 | 1,890,000 | 1,890,000 | - | - | Stock Option (Right to Buy) | |
| Conduit Pharmaceuticals Inc | James Bligh | Director, Interim CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jun 2024 | 37,272 | 37,272 | - | - | Common Stock |